Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2000-06-15
2001-10-30
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C435S235100, C435S236000, C435S237000, C435S245000
Reexamination Certificate
active
06309650
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to an attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell and a Japanese encephalitis vaccine comprising said attenuated virus.
2. Description of the Prior Art
Japanese encephalitis (JE) is a mosquito-borne arboviral disease of major or public health importance in Asia. More than 35,000 cases and 10,000 deaths are reported annually from that continent, but official reports undoubtedly underestimate the true number of cases (Okuno, T.
World Health Stat Q.
3: 120-31,1978; Umenei, T. et al.
Bull World Health Org.
63: 625-31, 1985). The illness may be manifested by a febrile headache syndrome, aseptic meningitis, or encephalitis and about half of the survivors tend to have permanent neurologic and psychiatric sequelae (Burke, D. S. et al. The Arbovirus:
Epidemiology and Ecology
3:63-92, 1988; Monath, T. P.
Virology
763-814, 1990).
JE virus is one of 66 Flaviviridae, enveloped, positive-sense, single stranded RNA viruses that largely are vector-borne (Chambers, T. J. et al.
Ann. Rev. Microbiol.
44:649-88, 1990). Morphologically, flaviviruses are spherical, approximately 40 nm in diameter, are composed of a lipid bilayer surrounding a neucleocapsid containing 11-kb genome complexed with a capsid (C) protein (Rice, C. M. et al.
Science
229:726-33, 1985). Surface projections on the membrane are composed of glycosylated envelope (E) and membrane (M) proteins. A pre-M glycoprotein, present in intracellular nascent virions, is cleaved to the M protein, found in mature extracellular virions. Important physiological activities are associated with the 53-kd E protein, including hemagglutination, viral neutralization, virion assembly, membrane fusion, and viral binding to cellular receptors (Koshini, E. et al.
Virol.
188:714-20, 1992).
There are three JE vaccines for humans (Tsai, T. et al.
Vaccines
671-713, 1993). Of the three, only inactivated JE vaccine produced in mouse brain is available internationally. One manufacturer, the Research Foundation for Microbial Diseases of Osaka University (Biken) produces most of the inactivated JE vaccine distributed internationally; that vaccine was licensed in 1992 in the USA where it is distributed by Connaught Laboratories, Inc., as JE-VAX™. Inactivated and live attenuated JE vaccine prepared in primary hamster kidney (PHK) cells are distributed solely in China.
Inactivated JE vaccine produced in mouse brains was licensed in Japan in 1954. Because it is produced by cerebral injection of infant mice, it is laborious to manufacture and concerns about the possibility of vaccine-related neurological side effect were raised. Though successive refinements in the manufacturing process have increased its purity and potency (Oya, A.
Vaccination Theory and Practice
69-82, 1975; Oya, A.
Acta Pediatr Jpn.
30:175-84, 1988; Takaku, K. Biken J. 11:25-39, 1968), a moderate frequency of local and mild systemic reactions have been reported until recently (Hoke, C. H. et al.
New Engl J Med.
319:608-14, 1988; Poland, J. D. et al.
J Infect Dis.
161:878-82, 1990; Sanchez, J. L. et al.
Lancet
335:972-73, 1990). Local tenderness, redness, and/or swelling at the injection site occur in 20% of vaccines. Mild systemic symptoms, chiefly headache, low-grade fever, myalgias, malaise, and gastrointestinal symptoms, are reported by 10 to 30% of vaccines. An apparently new pattern of adverse reactions including urticaria, angioedema, respiratory distress, erythema multiforme, erythema nosodum and severe neurological disorders have been reported since 1989, principally among travellers vaccinated in Australia, Europe, and North America (Anderson, M. M. et al.
Lancet.
337:1044, 1991; Ruff, T. A. et al.
Lancet
228:881-2, 1991). In addition, in 1992 and 1995 Ohtaki reported seven children with acute disseminated encephalomyelitis (ADEM) with changes on magnetic resonance images (MRI) after JE vaccination (Ohtaki, E. et al.
Pediatr Neurol.
8:137-9, 1992; Ohtaki, E. et al.
J Neurol Neurosurg Psychiatry
59:316-7, 1995). Also of note is that vaccination with rabies vaccine containing animal brain tissue has caused severe neurological complications (Plotkin, S. A. et al.
Vaccines
661-2, 1994). For these reasons, the WHO has designated JE vaccine development as a high priority.
More recently, inactivated and live attenuated JE vaccine of China have proven to be effective, eliciting high titers of virus-neutralizing antibody and conferring solid protection (Tsai, T. el al.
Vaccines
671-713, 1993). However, PHK cells in which Chinese vaccine were prepared are not approved by the World Health Organization (WHO) for viral vaccine production or licensed for human use by the developed countries. The principal disadvantage in using primary hamster cells for the production of vaccines is the uncertainty with regard to the quality of vaccine. Even if specific pathogen free hamsters are used, animals can unexpectedly become infected, being problematic for vaccine production. Occasionally an infection of this type could be undetected for along time. With these criticisms, further controlled studies of the safety of the vaccine are required to allow confidence regarding its widespread use. Another disadvantage of the vaccine production from primary cells is the low rate of harvest of the virus and high cost without allowing mass production.
In view of the above, there is a need for new JE vaccine which is produced in standard cell lines such as Vero or human diploid cells that have been accepted as human vaccine substrates, with good cost effectiveness. Vero cells are transformed but non-tumorigenic cells derived from monkey kidney. The Vero cell line is more advantageous than any other standard cell line in that Vero cells are more readily adaptable to large scale cell culture and as a transformed cell has an infinite life time.
It has now been found that JE virus can be grown in Vero cell culture. Considerable efforts had been made in the field of JE vaccine to produce vaccine in standard cells which permit effecting cell cultures at a large volume. Nevertheless, virus characterization including genetic stability, yield and process necessary for vaccine commercialization through cultivation with Vero cells had never met the requirements of human vaccine. Owing to these facts and to the difficulties of transposing a knowledge acquired in other virus cultures to JE virus, the prior art had not achieved success in the development of JE virus vaccine which is genetically stable and has a high immunogenic character from continuous cell lines. Among all these researches, none had resulted up to the present time in a new vaccine production which satisfies the criteria mentioned in this background.
The present invention suggests a development and a propagation of JE virus in continuous cell line, Vero cells for vaccine production which overcome previous problems in JE virus produced in mouse brain or primary cell lines. The present invention also identifies methodology developed to cultivate the JE virus and a downstream process for vaccine production with cost-effectiveness.
In addition, the present invention identifies methodology which improves upon the previously commercialized JE vaccines in the following ways.
1. Safety: The invented virus did not acquire the virulence through the Vero cell cultivation, reducing the hazards of production and affording an additional level of safety to recipients beyond that furnished by stringent control over the virus-inactivation process. This advantage has never been provided by the previously commercialized JE vaccines.
2. Increased supply in safer production substrate: The JE vaccine of the present invention is produced in the absence of bovine serum, making high yields and inexpensive and scalable production which are not achieved in the previously commercialized JE vaccines.
3. Less reactogenicity: No gelatin stabilizer is incorporated into the JE vaccine of the present invention, reducing the risk of vaccine r
Binn Leonard N.
Chung Yong Ju
Dubois Doria R.
Eckels Kenneth H.
Hong Sun Pyo
Arwine Elizabeth
Burns Doane Swecker & Mathis L.L.P.
Cheil Jedang Corporation
Foley Shanon A.
Housel James
LandOfFree
Attenuated Japanese encephalitis virus adapted to Vero cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated Japanese encephalitis virus adapted to Vero cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated Japanese encephalitis virus adapted to Vero cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2598147